Navigation Links
Sideeffects of Rosiglitazone in Type2 Diabetes Patients

The trade-offs between potential benefits and potential harms when rosiglitazone is used by people with type 2 diabetes has to be assessed .

This Cochrane Systematic Review analysed data from 18 trials that involved a total of 8432 people and found no evidence that rosiglitazone led to better patient outcomes when compared with other therapies.

Diabetic control (as measured by levels of HbA1c) was no better in patients given rosiglitazone when compared to other antidiabetic drugs. Patient oriented outcomes such as mortality, diabetes related morbidity, or quality of life were not addressed in most studies.

In addition to confirming the known risk of edema (people taking the treatment are at twice the risk of developing this condition) and an increase in body weight up to 5.0 kg, the authors found evidence from one large study indicating increased cardiovascular risk and an enhanced risk in women of having broken bones.

In people with type 2 diabetes, their body has a reduced ability to cause cells to remove glucose from the blood. The resulting high levels of blood-glucose can cause considerable damage especially to the eyes, nerves and kidneys.

Rosiglitazone is one of a range of drugs that increase cells sensitivity to insulin and therefore may restore some of the normal function.

Unfortunately, the published studies where people have taken rosiglitazone for at least 24 weeks do not give relevant data about issues like mortality, morbidity, and changes in health-related quality of life, says lead author Associate Professor Bernd Richter, who works at the Department of General Practice, in Duesseldorf.

Studies on patient-oriented outcomes are urgently needed, although it is questionable whether new studies with rosiglitazone will be ethical given the fact that less dangerous therapeutic alternatives exist, says Richter.


'"/>




Page: 1

Related medicine news :

1. Oral Drug Rosiglitazone Could Help Prevent Type 2 Diabetes
2. Patients Advised for Using Rosiglitazone to See Their Doctor - ADA
3. Less Information on Dietary Treatment in Type2 Diabetes
4. Alternative Option for Type2 Diabetes Treatment
5. Deep Insights into Type2 Diabetes by Wesley Researchers
6. Is Diabetes the Leading Cause of Kidney Failure in India
7. Diabetes and Depression often go hand-in-hand
8. Thirty minutes of work up per day reduces the risk of Diabetes
9. Diabetes on the rise
10. Irregular Periods Linked to Diabetes
11. Cinnamon combats Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/25/2016)... ... May 25, 2016 , ... The Georgia State University College of Law new ... Urban Design Commission. , The annual award recognizes projects, programs, individuals and organizations that ... preservation of its physical heritage and the balance between the old and the new. ...
(Date:5/25/2016)... ... 2016 , ... A new update to Xsens popular data analysis ... a common Wi-Fi network and a mobile device. When paired with Xsens MVN or ... and use a mobile device to control the recording. , “The update adds ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... One Florida-based ... potential patients, according to an article published May 13th on Vanity Fair. ... comfortable with having snippets of their procedures broadcast to more than 800,000 Snapchat fans. ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Bank of America Charitable Foundation has awarded ... provide veterans a pathway to employment and successful careers in healthcare. On Wednesday, May ... Hallack, President and CEO of Medisend, parent organization and home of the General Myers ...
(Date:5/25/2016)... ... May 25, 2016 , ... New studies ... of injured workers across 15 states. The outcomes examined in these studies include ... medical care, and satisfaction with medical care. , “The goal of the studies ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
Breaking Medicine Technology: